Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 4/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30607714 | 0.81 | PARP1 (0.48) | GRM1GRM5GPR119NR1H2NR1H3 | |
| SCHEMBL20139227 | 0.80 | GPR119 (0.53) | GRM1GRM5GPR119CHRM4AR | |
| SCHEMBL20139986 | 0.80 | GPR119 (0.46) | GRM1GRM5GPR119NR1H2NR1H3 | |
| SCHEMBL652792 | 0.75 | GRM5 (0.53) | GRM5GPR119 | |
| SCHEMBL12835989 | 0.75 | PIM1 (0.58) | — | |
| SCHEMBL20156957 | 0.74 | GPR119 (0.47) | GRM5GPR119 | |
| SCHEMBL2840732 | 0.74 | GRM5 (0.46) | GRM1GRM5GPR119NR1H2NR1H3 | |
| SCHEMBL13841896 | 0.74 | GRM5 (0.46) | GRM1GRM5GPR119NR1H2NR1H3 | |
| SCHEMBL2456832 | 0.74 | GRM1 (0.56) | GRM1GRM5GPR119NR1H2 | |
| SCHEMBL13088807 | 0.74 | UCHL1 (0.56) | GRM5UCHL1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018089433-A1 | PHENYL mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |